Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension

Journal of Human Hypertension

Volumn 20, Issue 4, 2006, Pages 299-301

  Rump, L Christian ^a   Ambrosioni, E ^b   Burnier, M ^c   Horl W ^d   Rabelink, A J ^e  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; OLMESARTAN; PLACEBO; THIAZIDE DIURETIC AGENT;

ADULT; BACKACHE; BLOOD PRESSURE REGULATION; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG WITHDRAWAL; EUROPE; FATIGUE; FEASIBILITY STUDY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; INFORMED CONSENT; LETTER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SPHYGMOMANOMETER; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TREATMENT OUTCOME;

EID: 33645074442     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001984     Document Type: Letter

References (12)

1. WHO-ISH Hypertension Guidelines Committee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-185.
2. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
4. 3 European Society of Hypertension. European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
5. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
6. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
7. Cook NR, Cohen J, Hekbert PR, Taylor JO, Hennekens CH. Implication of small reductions in diastolic blood pressure for primary prevention. Arch Int Med 1995; 155: 701-709.
8. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999; 100: 354-360.
9. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001; 358: 1305-1315.
10. Asmar R, Lacourciere Y. A new approach to assessing antihypertensive therapy: Effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens 2000; 18: 1683-1690.
11. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87: 37C-43C.
12. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.